Securities code: 603858 securities abbreviation: Shandong Buchang Pharmaceuticals Co.Ltd(603858) Announcement No.: 2022-004 Shandong Buchang Pharmaceuticals Co.Ltd(603858)
Announcement on abnormal fluctuations in stock trading
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of the announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of the contents.
Important content tips:
The deviation of the closing price of the company’s stock trading for three consecutive trading days on January 14, January 17 and January 18, 2022 has reached 20%, which belongs to abnormal fluctuation of stock trading. After the company’s self-examination and verification with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there are no major matters that should be disclosed but not disclosed.
1、 Details of abnormal fluctuations in stock trading
Shandong Buchang Pharmaceuticals Co.Ltd(603858) (hereinafter referred to as “the company”) shares traded for three consecutive trading days on January 14, January 17 and January 18, 2022. The cumulative deviation of the closing price increase reached 20%. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to the abnormal fluctuation of stock trading. 2、 Relevant information concerned and verified by the company
(I) production and operation
According to the company’s self inspection, the company’s current production and operation is normal, and there is no major information that should be disclosed but not disclosed.
(II) major events
After the company’s self-examination and verification with the controlling shareholder and actual controller of the company, the controlling shareholder and actual controller of the company do not have any major information that should be disclosed but not disclosed by the company, including but not limited to major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase, equity incentive, bankruptcy reorganization Major business cooperation, introduction of strategic investors and other major issues.
(III) media reports, market rumors and hot concepts
The company has not found any media reports or market rumors that may have a great impact on the company’s stock trading price, and has not found any other major information that may have a great impact on the company’s stock price.
(IV) other share sensitive information
After verification, the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell the company’s shares during the abnormal fluctuation of this stock trading.
3、 Relevant risk tips
The closing price of the company’s stock trading has deviated by 20% for three consecutive trading days on January 14, January 17 and January 18, 2022. The company invites investors to pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
The board of directors of the company solemnly reminds investors that the company will perform the obligation of information disclosure in strict accordance with relevant laws and regulations. The newspapers and periodicals designated by the company for information disclosure are China Securities News, Shanghai Securities News, securities times and Securities Daily, and the information disclosure website is the website of Shanghai Stock Exchange (www.sse. Com. CN.), The information released by the company shall be subject to the announcement published in the above designated newspapers and websites. Please pay attention to the investment risks.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that according to the relevant provisions of the Listing Rules of Shanghai Stock Exchange, the company currently has no matters that should be disclosed but not disclosed, or the planning, negotiation, intention and agreement related to such matters, and the board of directors has not been informed that the company has matters that should be disclosed but not disclosed according to the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
It is hereby announced.
Shandong Buchang Pharmaceuticals Co.Ltd(603858) board of directors January 19, 2022
